At Centauri we seek to tackle life-threatening infectious diseases in the most vulnerable patients.

Alphamers

Our science

Centauri Therapeutics is an immunotherapy company focused on infectious diseases. All projects harness a powerful and clinically validated immune mechanism which redirects naturally existing antibodies to treat life-threatening diseases. Centauri holds an exclusive worldwide license to exploit the Alphamer® immunotherapeutics platform within the field of infectious disea

7.0m

immunocompromised people in the United States 1

60%

of haematological cancer deaths are infection related 2

$4.6bn

health care costs in the US to treat six antibiotic resistance threats 3

67,000

deaths annually in Europe and US due to drug-resistant bacterial infections 4 5

Bacteria

Latest News and Articles

Centauri Therapeutics attended ID Week 2022

October 27, 2022

Jennifer Schneider, CEO and Helen Bright, VP of Research &…

Read More

Centauri Therapeutics Dr Mike Westby attended ESCMID/ASM Conference 2022

October 27, 2022

Dublin, 4th to 7th October 2022 – Dr Mike Westby, Centauri’s…

Read More

Centauri welcomes Alison Gallop

October 17, 2022

Centauri is pleased to welcome Alison Gallop to the team…

Read More